Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Renal impairment in type 2 diabetes limits available glucose-lowering treatment options. This trial was conducted to establish the efficacy and safety of liraglutide as an add-on to existing glucose-lowering medications in patients with inadequately controlled type 2 diabetes and moderate renal impairment. RESEARCH DESIGN AND METHODS: In this 26-week, double-blind trial, 279 patients with HbA1c 7–10%, BMI 20–45 kg/m2, and moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2; MDRD) were randomized (1:1) to once-daily liraglutide 1.8 mg (n = 140) or placebo (n = 139). RESULTS: The estimated treatment difference in HbA1c from baseline to week 26 was −0.66% (−7.25 mmol/mol) (95% CI −0.90 to −0.43 [−9.82 to −4.69]), P < 0.0001). Fasting plasma glucose decreased more with liraglutide (−1.22 mmol/L [−22.0 mg/dL]) than with placebo (−0.57 mmol/L [−10.3 mg/dL], P = 0.036). There was a greater reduction in body weight with liraglutide (−2.41 kg) than with placebo (−1.09 kg, P = 0.0052). No changes in renal function were observed (eGFR relative ratio to baseline: −1% liraglutide, +1% placebo; estimated treatment ratio [ETR] 0.98, P = 0.36). The most common adverse events were gastrointestinal (GI) adverse effects (liraglutide, 35.7%; placebo, 17.5%). No difference in hypoglycemic episodes was observed between treatment groups (event rate/100 patient-years of exposure: liraglutide, 30.47; placebo, 40.08; P = 0.54). The estimated ratio to baseline for lipase was 1.33 for liraglutide and 0.97 for placebo (ETR 1.37, P < 0.0001). CONCLUSIONS: Liraglutide did not affect renal function and demonstrated better glycemic control, with no increase in hypoglycemia risk but with higher withdrawals due to GI adverse events than placebo in patients with type 2 diabetes and moderate renal impairment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike the LEADER and SCALE trials, in the LIRA-RENAL trial liraglutide was found to be ineffective in improving renal outcomes in a sample of 279 diabetic patients with moderate CKD (eGFR 30–59 mL/min/1.73 m2).”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [44]
In the citing paper
“The authors found no difference in terms of eGFR and UACR compared with placebo after 26 weeks of treatment [44].”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [44]
Citations
Cites
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725 · cited 1×
“Safety assessments included adverse events (AEs), change from baseline to Week 26 in renal function (eGFR [MDRD] (19), urinary albumin:creatinine ratio [UACR]), amylase, lipase and pulse rate.”
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.73 · Cited by 3,206
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440 · cited 1×
“Albuminuria is not only a marker for kidney damage but it is also a cardiovascular risk factor (33,34).”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Research works printed but not linked: 1
- Scott, 2014, Efficacy and safety of liraglutide versus placebo by eGFR subgroup in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized trial (Abstract), J Am Soc Nephrol, 25, 75A
Cited by
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationMolecular mechanisms of ROS production and oxidative stress in diabetes
Newsholme, P., Cruzat, V. F., Keane, K. N., Carlessi, R., & de Bittencourt, P. I. H. (2016) · Biochemical Journal · doi:10.1042/bcj20160503c · Cited by 878
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
“13,14 Alternatively, differences between the results in this trial and the encouraging earlier study using recombinant GLP-17 could be due to the cardioprotective roles of GLP-1 metabolites, such as GLP-1(9-36)amide, which act independently of the GLP-1 receptor and are not generated by GLP-1 agonists like liraglutide.”
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
“In the LIRA-RENAL trial 144 , 279 patients with T2DM and moderate renal impairment (eGFR 30–59 ml/min/1.73 m 2 ) were randomly assigned to liraglutide 1.8 mg or placebo for 26 weeks.”
InfluentialMosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351
Self-citationLiraglutide for weight management: a critical review of the evidence
Mehta, A., Marso, S. P., & Neeland, I. J. (2017) · Obesity Science & Practice · doi:10.1002/osp4.84 · Cited by 311
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Muskiet, M. H. A., Tonneijck, L., Huang, Y., Liu, M., Saremi, A., Heerspink, H. J. L., & van Raalte, D. H. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30268-7 · Cited by 259
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
GLP-1 receptor agonists and kidney protection
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S. (2019) · Medicina · doi:10.3390/medicina55060233 · Cited by 173
“The data from the Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA RENAL) trial, which investigated the effects of liraglutide in patients with T2DM with moderate renal impairment, showed that liraglutide did no…”
MethodMann, J. F. E., Fonseca, V., Mosenzon, O., Raz, I., Goldman, B., Idorn, T., von Scholten, B. J., Poulter, N. R., & The LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Circulation · doi:10.1161/circulationaha.118.036418 · Cited by 147
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144
“Semaglutide effected a 36% reduction (HR 0.64 (95% CI 0.46–0.88, p = 0.005)) in a secondary combined kidney endpoint (new-onset macroalbuminuria, doubling serum creatinine reaching an eGFR 45 mL/min/1.73 m2, initiation of renal replacement therapy or renal death).”
BackgroundInfluentialThethi, T. K., Pratley, R., & Meier, J. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14054 · Cited by 134
Marbury, T. C., Flint, A., Jacobsen, J. B., Derving Karsbøl, J., & Lasseter, K. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0528-2 · Cited by 130
“in pharmacokinetics and pharmacodynamics in patients with RI versus those with normal renal function, are welltolerated, and exhibit a low risk of hypoglycemia, irrespective of renal function [24, 25, 29, 30].”
BackgroundSkov, J., Pedersen, M., Holst, J. J., Madsen, B., Goetze, J. P., Rittig, S., Jonassen, T., Frøkiær, J., Dejgaard, A., & Christiansen, J. S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12651 · Cited by 128
“Liraglutide improved glycaemic control but did not change the creatinine-based GFR estimation and did not significantly decrease albuminuria [20].”
BackgroundGLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms
Kawanami, D., & Takashi, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00967 · Cited by 129
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Granhall, C., Søndergaard, F. L., Thomsen, M., & Anderson, T. W. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0649-2 · Cited by 125
“patients with moderate renal impairment, liraglutide did not affect renal function; withdrawals due to gastrointestinal AEs were higher than with placebo but with no increase in hypoglycaemia risk [32].”
BackgroundResultMedication Safety Principles and Practice in CKD
Whittaker, C. F., Miklich, M. A., Patel, R. S., & Fink, J. C. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00580118 · Cited by 141
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., ter Wee, P. M., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes Care · doi:10.2337/dc16-1371 · Cited by 113
New pharmacological strategies for protecting kidney function in type 2 diabetes
Muskiet, M. H. A., Wheeler, D. C., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30263-8 · Cited by 107
The effect of liraglutide on renal function: A randomized clinical trial
von Scholten, B. J., Persson, F., Rosenlund, S., Hovind, P., Faber, J., Hansen, T. W., & Rossing, P. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12808 · Cited by 105
Self-citationThe potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Thomas, M. C. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30069-1 · Cited by 111
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
Kelly, M. S., Lewis, J., Huntsberry, A. M., Dea, L., & Portillo, I. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1549459 · Cited by 94
Chiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
Davies, M. J., Chatterjee, S., & Khunti, K. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s82008 · Cited by 84
“5%).(106) Jacobsen et al(100) investigated the effect of renal impairment on the PK of liraglutide in patients with T2D and normal renal function or stages 2–5 CKD.”
Self-citationTherapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016121372 · Cited by 75
Cardiovascular Disease and Diabetic Kidney Disease
Maqbool, M., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.003 · Cited by 78
Mosenzon, O., Prato, S. D., Schechter, M., Leiter, L. A., Ceriello, A., DeFronzo, R. A., & Raz, I. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01281-y · Cited by 76
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · UCL Discovery (University College London) · Cited by 71
Mansur, R. B., Zugman, A., Ahmed, J., Cha, D. S., Subramaniapillai, M., Lee, Y. L., Lovshin, J. A., Lee, J. G., Lee, J.-H., Drobinin, V., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.433 · Cited by 73
Anti-fibrotic treatments: A review of clinical evidence
Allinovi, M., Chiara, L. D., Angelotti, M. L., Becherucci, F., & Romagnani, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.017 · Cited by 74
Ninčević, V., Kolarić, T. O., Roguljić, H., Kizivat, T., Smolić, M., & Bilić-Čurčić, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235831 · Cited by 77
“This was also suggested during the LIRA-RENAL trial when lower concentration of inflammation marker hsCRP was obtained in liraglutid treated group in comparison with placebo [63].”
ResultAn evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1695779 · Cited by 65
“8 mg daily did not affect renal function and demonstrated better glycemic control, with no increase in hypoglycemia risk compared to placebo [66].”
BackgroundGlucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 74
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 73
Chen, J., Hsu, T., Liu, J.-H., Pan, H., Lai, C., Yang, S., & Wu, V. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.11.013 · Cited by 81
Scheen, A. J. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.008 · Cited by 60
Rahhal, M.-N., Gharaibeh, N. E., Rahimi, L., & Ismail‐Beigi, F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00286 · Cited by 68
Diabetic nephropathy: newer therapeutic perspectives
Keri, K., Samji, N. S., & Blumenthal, S. S. (2018) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2018.1500423 · Cited by 70
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 111
Sloan, L. A. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12969 · Cited by 58
“0001), with no effect on renal function as measured by UACR or eGFR.(54) In a separate RCT of 24 patients with dialysisdependent ESRD, liraglutide reduced HbA1c at 12 weeks (−0.”
BackgroundKalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 70
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Mosterd, C. M., Bjornstad, P., & van Raalte, D. H. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00738-9 · Cited by 56
Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac069 · Cited by 54
GLP-1 Agonists in Type 1 Diabetes Mellitus
Janzen, K. M., Steuber, T. D., & Nisly, S. A. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016651279 · Cited by 60
Yeh, T., Tsai, M.-C., Tsai, W.-H., Tu, Y., & Chien, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278685 · Cited by 57
Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Zhao, X., Huang, K., Zheng, M., & Duan, J. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0332-5 · Cited by 56
Safety of liraglutide in type 2 diabetes and chronic kidney disease
Mann, J. F. E., Fonseca, V. A., Poulter, N. R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., Mosenzon, O., & on behalf of the LEADER Trial Investigators (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11881019 · Cited by 50
Caruso, I., & Giorgino, F. (2024) · Endocrine · doi:10.1007/s12020-024-03757-9 · Cited by 60
Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients
Lovre, D., Shah, S., Sihota, A., & Fonseca, V. A. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.006 · Cited by 46
Acute kidney injury in diabetes mellitus: Epidemiology, diagnostic, and therapeutic concepts
Gui, Y., Palanza, Z., Fu, H., & Zhou, D. F. (2023) · The FASEB Journal · doi:10.1096/fj.202201340rr · Cited by 60
Sánchez, J. J. G., Thompson, J. C., Scott, D. A., Evans, R., Rao, N., Sörstadius, E., James, G., NOLAN, S. T., Wittbrodt, E. T., Sultan, A. A., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-02006-z · Cited by 64
Self-citationAviles Bueno, B., Soler, M. J., Perez-Belmonte, L., Jimenez Millan, A., Rivas Ruiz, F., & Garcia de Lucas, M. D. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac096 · Cited by 43
Yu, M., Wang, R., Pei, L., Zhang, X., Wei, J., Wen, Y., Liu, H., Ye, H., Wang, J., & Wang, L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01118-6 · Cited by 44
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Yin, W. L., Bain, S. C., & Min, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00798-x · Cited by 48
Self-citationHu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 48
“…qd+met+TZD 178 55±10 57 33.2±5.4 9±6 8.5±1.2 / Liraglutide 1.8mg qd+met+TZD 178 55±11 51 33.5±5.1 9±6 8.6±1.2 / PBO+met+TZD 177 55±10 62 33.9±5.2 9±6 8.4±1.2 / Ahmann, 2015Ref.96 26 weeks Liraglutide 1.8mg qd+insulin±met 225 59.3±9.2 53.3 32.3±5.6 12.1±7.1 8.2±0.8 90.2±20.0 PBO+insulin±met…”
InfluentialEnterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota
Ni, Y., Zheng, L., Nan, S., Ke, L., Fu, Z., & Jin, J. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022140 · Cited by 49
Cowart, K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028019889064 · Cited by 42
“%) as compared with placebo (4%).19 As was demonstrated in PIONEER 5, and consistent with findings from the LIRA-RENAL trial, gastrointestinal events were more common in patients with stage 3A versus 3B CKD.22,27 Across the PIONEER program, more patients treated with oral semaglutide (~5% to 7”
ResultInfluentialHowse, P. M., Chibrikova, L., Twells, L., Barrett, B. J., & Gamble, J. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.06.014 · Cited by 47
Banerjee, M., Pal, R., Mukhopadhyay, S., & Nair, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad076 · Cited by 52
GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
Dieter, B. P., Alicic, R. Z., & Tuttle, K. R. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00211.2018 · Cited by 38
Consoli, A., Formoso, G., BALDASSARRE, M. P. A., & Febo, F. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1428305 · Cited by 44
Sivalingam, S., Wasehuus, V. S., Rotbain Curovic, V., Blond, M. B., Hansen, T. W., Persson, F., & Rossing, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15287 · Cited by 34
Self-citationKo, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 56
Toxicity of Metformin and Hypoglycemic Therapies
Akhter, M. S., & Uppal, P. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.004 · Cited by 40
Yamada, S., Tanabe, J., Ogura, Y., Nagai, Y., Sugaya, T., Ohata, K., Natsuki, Y., Ichikawa, D., Watanabe, S., Inoue, K., et al. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-02007-2 · Cited by 35
Yuan, D., Sharma, H., Krishnan, A., Vangaveti, V., & Malabu, U. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14776 · Cited by 41
“Therefore, in total, 22 papers featuring 27 studies involving 39 714 patients with T2DM were included in this systematic review (one paper was a posthoc analysis featuring six studies).(9,10,12,13,18-35) All studies were included in the meta-analysis.”
BackgroundWajdlich, M. J., & Nowicki, M. P. (2024) · Scientific Reports · doi:10.1038/s41598-024-55724-z · Cited by 43
Li, M., Yang, Y., Jiang, D.-Q., Ying, M., Wang, Y., & Zhao, R. (2017) · Medicine · doi:10.1097/md.0000000000008161 · Cited by 38
Renal protection with glucagon-like peptide-1 receptor agonists
Vitale, M., Haxhi, J., Cirrito, T., & Pugliese, G. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.018 · Cited by 38
Tong, L., & Adler, S. G. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1457397 · Cited by 40
“73 m(2)) [82] ● LEADER: reduced risk of major adverse CV events (13% reduction), death from CV causes (22% reduction), and death from any cause (15% reduction) vs.”
BackgroundAlkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
“The safety and efficacy of liraglutide and dulaglutide in individuals with moderate-to-severe renal impairment has been evaluated in the Phase III LIRA-RENAL and AWARD-7 studies, respectively, with both GLP-1RAs demonstrating improved glycemic control in this population [128,129].”
van Baar, M. J. B., van der Aart, A. B., Hoogenberg, K., Joles, J. A., Heerspink, H. J. L., & van Raalte, D. H. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819865398 · Cited by 33
Use of Glucose-Lowering Agents in Diabetes and CKD
Alicic, R. Z., Neumiller, J. J., Galindo, R. J., & Tuttle, K. R. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.09.018 · Cited by 38
“Notably, the weight loss effect is preserved in patients with CKD.(132,141) KDIGO preferentially recommends addition of a long-acting GLP-1RA (with proven cardiovascular benefits) in patients with T2D and CKD who need additional glucose lowering despite recommended firstline therapy with metformin plus a SGLT2 inhibit…”
BackgroundInfluentialChang, K.-C., Shao, S.-C., Kuo, S., Yang, C.-Y., Chen, H.-Y., Chan, Y.-Y., & Ou, H.-T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01148-8 · Cited by 28
“, liraglutide versus placebo [39]) or reduced eGFR declines (eGFR preservation) (i.”
BackgroundVanek, L., Kurnikowski, A., Krenn, S., Mussnig, S., & Hecking, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15967 · Cited by 28
The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis
Sasaki, T., Giang, S. M.-L., Wu, J., Yokoo, T., Gallagher, M., Bellomo, R., & Wang, Y. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf193 · Cited by 41
Inpatient Glycemic Management in the Setting of Renal Insufficiency/Failure/Dialysis
Iyengar, R., Franzese, J., & Gianchandani, R. Y. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1044-y · Cited by 31
Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 41
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
Rroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 34
“Studies like HARMONY 8 [41], LIRA-RENAL [42], AWARD-7 [43], and PIONEER 5 [44] compared GLP-1RAs to other treatments such as sitagliptin, placebo, or insulin glargine, demonstrating GLP-1RAs’ superiority or comparable efficacy in controlling glycemia.”
BackgroundMethodUpdike, W. H., Pane, O., Franks, R. B., Saber, F., Abdeen, F., Balazy, D. D., & Carris, N. W. (2021) · Drugs · doi:10.1007/s40265-021-01525-x · Cited by 30
Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
Tommerdahl, K. L., Nadeau, K. J., & Bjornstad, P. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.001 · Cited by 29
Boye, K. S., Botros, F. T., Haupt, A., Woodward, B., & Lage, M. J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0377-5 · Cited by 23
Muskiet, M. H. A., Bunck, M. C. M., Heine, R. J., Cornér, A., Yki‐Järvinen, H., Eliasson, B., Joles, J. A., Diamant, M., Tonneijck, L., & van Raalte, D. H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.001 · Cited by 23
“(24) Although similar suggestive falls in eGFR were seen promptly after liraglutide-treatment (13,14,26), these changes did not differ from placebo, and were quantitatively smaller than those seen upon RAS- and SGLT2-inhibition.”
BackgroundWei, W., Buysman, E. K., Grabner, M., Xie, L., Brekke, L. N., Ke, X., Chu, J. W., & LEVIN, P. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12828 · Cited by 22
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
Hanefeld, M., Arteaga, J. M., Leiter, L. A., Marchesini, G., Nikonova, E., Shestakova, M., Stager, W., & Gómez‐Huelgas, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12986 · Cited by 22
“Further data indicate that the glycaemic efficacy of liraglutide does not appear to be affected by moderate impairment.(11) Elimination of lixisenatide, a once-daily, injectable, prandial GLP-1 RA, is presumed to occur via renal filtration, tubular reabsorption and metabolic catabolism; the resulting metabolites do no…”
BackgroundInfluentialBomholt, T., Idorn, T., Knop, F. K., Jørgensen, M. B., Ranjan, A. G., Resuli, M., Hansen, P. M., Borg, R., Persson, F., Feldt‐Rasmussen, B., et al. (2020) · The Nephron journals/Nephron journals · doi:10.1159/000510613 · Cited by 26
Role of the Intestine and Its Gut Microbiota in Metabolic Syndrome and Obesity
Busch, C. B. E., Bergman, J. J. G. H. M., Nieuwdorp, M., & van Baar, A. C. G. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002730 · Cited by 27
Górriz, J. L., Romera, I., Cobo, A., O’Brien, P. D., & Merino-Torres, J. F. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01198-5 · Cited by 31
Anti-obesity pharmacotherapy in adults with chronic kidney disease
Taber-Hight, E., Gilmore, A. C., & Friedman, A. N. (2023) · Kidney International · doi:10.1016/j.kint.2023.10.014 · Cited by 22
Lullo, L. D., Mangano, M., Ronco, C., Bàrbera, V., Pascalis, A. D., Bellasi, A., Russo, D., Iorio, B. R. D., & Cozzolino, M. G. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.005 · Cited by 25
“The most frequent side effects were represented by gastrointestinal symptoms (dyspepsia, vomiting, diarrhea), and headache [75].”
BackgroundGonzález‐González, J. G., Solís, R. C., González-Colmenero, A. D., Raygoza-Cortez, K., Moreno-Peña, P. J., Sánchez, A. L., McCoy, R. G., Ospina, N. S., Maraka, S., Brito, J. P., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109821 · Cited by 22
Zu, C., Liu, M., Su, X., Wei, Y., Meng, Q., Liu, C., Ye, Z., Gan, X., Zhang, Y., He, P., et al. (2023) · Diabetes Care · doi:10.2337/dc23-1727 · Cited by 21
Effects of incretin-based therapies on renal function
Tsimihodimos, V., & Elisaf, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.049 · Cited by 22
“…that the increased delivery of sodium to the distal parts of the nephron increases the resistance of the afferent arteriole thus decreasing the intaglomerular pressure and preventing the hyperfiltration that commonly characterises the early stages of diabetic nephropathy (Davies et al., 2016).”
BackgroundResultInfluentialRondinelli, M., Rossi, A., Gandolfi, A., Saponaro, F., Bucciarelli, L. G., Adda, G., Molinari, C., Montefusco, L. B., Specchia, C., Rossi, M. C., et al. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.001 · Cited by 20
Metadata
- Authors
- Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E.
- Affiliations
- University of Leicester (GB)
- Swansea University (GB)
- Weill Cornell Medical College in Qatar (QA)
- Steno Diabetes Center, Gentofte, Denmark
- Clinical Research Development Associates, Rosedale, NY
- Department of Diabetic Nephropathy, Endocrinology Research Centre, Moscow, Russia
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Emory University (US)
- Corresponding author
- Davies, Melanie J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-12-17
- Volume
- 39
- Issue
- 2
- Pages
- 222-230
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2236659707
- Cited by
- 235
- References
- 35
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 17 · 2023: 28 · 2022: 18 · 2021: 19 · 2020: 24 · 2019: 22 · 2018: 28 · 2017: 24 · 2016: 16
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- liraglutide, type 2 diabetes, renal dysfunction, glycemic control, HbA1c, fasting blood glucose, weight loss, renal function, lipase, hypoglycemia, gastrointestinal adverse effects, GLP-1 receptor agonists, GIP receptor agonist, GIP/GLP-1 receptor agonist
- MeSH terms
- Liraglutide, Adolescent, Adult, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Gastrointestinal Tract, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.